Welcome
Support Centre
26 October 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
A phase II/III, observer-blind, randomised, active controlled study to compare the safety and immunogenicity of a meningococcal A conjugate vaccine (PsA-TT) with meningococcal ACWY polysaccharide vaccine administered in healthy subjects 2 to 29 years of age
ISRCTN ISRCTN87739946
DOI 10.1186/ISRCTN87739946
ClinicalTrials.gov identifier
EudraCT number
Public title A phase II/III, observer-blind, randomised, active controlled study to compare the safety and immunogenicity of a meningococcal A conjugate vaccine (PsA-TT) with meningococcal ACWY polysaccharide vaccine administered in healthy subjects 2 to 29 years of age
Scientific title
Acronym N/A
Serial number at source RPC217; PsA-TT-003
Study hypothesis To compare the immunogenicity of a single dose of the PsA-TT vaccine with that of the Meningococcal A component of the PsACWY vaccine at 28 days after vaccination.
Lay summary Not provided at time of registration
Ethics approval Ethics approval received from:
1. The Gambia Government/Medical Research Council (MRC) Laboratories Joint Ethic Committee on the 30th July 2007 (ref: L2007.56)
2. Ethics committee of the National Center for Scientific Research (Centre National de la Recherche Scientifique [CNRS]) on the 8th August 2007 (ref: 127MSPM/DS/CNRS)
3. Ethics committee of the Faculty of Medicine Pharmacy and Odonto-stomatology (Faculte de Medecine de Pharmacie et d'Odonto-Stomatologie [FMPOS]) on the 23rd July 2007 (ref: 0750/FMPOS)
Study design Phase II/III, observer-blind, randomised, active controlled study
Countries of recruitment Gambia, Mali, Senegal
Disease/condition/study domain Bacterial meningitis
Participants - inclusion criteria A subject will be eligible for inclusion if ALL of the following apply at the time of enrolment:
1. Age 2 to 29 years of age (both included)
2. Written informed consent obtained from the subject (for subjects equal to 18 years of age)/parents or legal guardian (for subjects less than 18 years of age)
3. Written informed assent from the subject if and as appropriate within the participating community (e.g., for subjects equal to 13 years of age in the Malian site, for subjects equal to 15 years of age in the Senegal site or for subjects equal to 12 years of age in the Gambia site)
4. Free of obvious health problems as established by medical history including physical examination and clinical judgement of the investigator
5. Subject/parents, or legal guardian capable and willing to come/bring their child or to receive home visits for all follow-up visits
6. Residence in the study area
7. Fully vaccinated according to the local Expanded Program on Immunisation (EPI) schedule (for subjects 2 to 3 years of age only)
Participants - exclusion criteria Subjects with any of the following criteria at study entry will not be eligible for participation:
1. Previous vaccination against Neisseria meningitidis during the six previous years
2. Known exposure to Neisseria meningitidis during the three previous months
3. History of allergic disease or known hypersensitivity to any component of the two study vaccines and/or following administration of vaccines included in the local program of immunisation
4. Administration of any other vaccine within 60 days prior to administration of study vaccines or planned vaccination during the first 28 days after the study vaccination
5. Use of any investigational or non-registered drug within 90 days prior to the administration of study vaccines
6. Administration of immunoglobulins and/or any blood products within 30 days prior to the administration of study vaccines or planned administration during the study period
7. Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying agents within 90 days prior to the administration of study vaccines (Including systemic corticosteroids, this means prednisone, or equivalent, greater than 0.5 mg/kg/day; topical steroids including inhaled steroids are allowed)
8. A family history of congenital or hereditary immunodeficiency
9. History of meningitis or seizures or any neurological disorder
10. Major congenital defects or serious chronic illness, including malnutrition (as per investigator's judgement)
11. Acute disease at the time of enrolment (acute disease is defined as the presence of a moderate or severe illness with or without fever) is a temporary exclusion
12. Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by medical history, physical examination or laboratory tests, which in the opinion of the investigator, might interfere with the study objectives
13. Any condition or criteria that in the opinion of the investigator might compromise the well being of the subject or the compliance with study procedures or interfere with the outcome of the study
14. Non residence in the study area or intent to move out within one year
15. Pregnancy or lactation (a negative pregnancy test will be required before vaccination for all women of childbearing potential)
16. Previous inclusion of five family members in the study (i.e., subjects belonging to the same family - biological father, mother, child, and brothers and sisters may be included up to a maximum of five members from the same family)
Anticipated start date 20/08/2007
Anticipated end date 20/09/2008
Status of trial Completed
Patient information material
Target number of participants 900
Interventions 1. One 0.5 ml dose out of a decadose vial of PsA-TT vaccine will be injected intramuscularly (IM) in the right deltoid
2. One 0.5 ml dose of PsACWY vaccine will be injected IM in the right deltoid

Joint sponsor:
Program for Appropriate Technology in Health (PATH) (USA)
1455 NW Leary Way
Seattle
WA 98107
U.S.A.
Tel: +1 206 285 3500
Fax: +1 206 285 6619

Principal Investigators:
Dr Samba Sow (PI for Mali)
Centre pour les Vaccins en Developpement (CVD) Mali
Centre National d'Appui a la lutte contre la Maladie (CNAM)
Ministere de la Sante
Ex-Institut Marchoux
BP 251 Bamako
Mali
Tel: +223 (0)674 8947
Fax: +223 (0)222 2883
Email: ssow@medicine.umaryland.edu

Dr Brown Okoko (PI for The Gambia)
Medical Research Council (MRC) Laboratories
PO Box 273
Fajara
The Gambia
Tel: +220 (0)779 2510
Fax: +220 (0)449 6513
Email: bokoko@mrc.gm

Dr Aldiouma Diallo (PI for Senegal)
Institut de Recherche pour le Développement (IRD)
BP 1386
CP 18524 Dakar
Senegal
Tel: +220 (0)654 1333
Email: diallo@ird.sn
Primary outcome measure(s) The percentage of subjects who show a seroconversion for anti-Meningococcal Polysaccharide A (MenPsA) antibodies, i.e. a four-fold increase in post-immunisation serum titre with respect to pre-immunisation serum titre, at 28 days after a single vaccine dose, as measured by rabbit complement Serum Bactericidal Assay (rSBA).
Secondary outcome measure(s) Safety:
1. The percentage of subjects with local and systemic post-immunisation reactions during the first four days, adverse events and Serious Adverse Events (SAEs), as measured at 4 and 28 days after vaccination (reactogenicity and short-term safety)
2. The percentage of subjects with SAEs during the entire study duration, as measured at 182 days (6 months) and 364 days (1 year) (long-term safety)

Immunogenicity:
1. The percentage of subjects with anti-MenPsA titre greater than or equal to 1:8 (defined as seroprotection to MenA) at 28 days after a single vaccine dose, as measured by rSBA assay. The percentage of subjects with anti-MenPsA titer greater than or equal to 1:128 (defined as long-term seroprotection to MenA) will be also considered
2. Geometric Mean Titres (GMTs) for anti-MenPsA antibodies at 28 days after a single vaccine dose, as measured by rSBA assay
3. Evaluation of reverse cumulative distribution curves for MenPsA antibody titres at 28 days after a single vaccine dose, as measured by rSBA assay
4. The percentage of subjects who show a seroconversion for anti-MenPsA total Immunoglobulin G (IgG), i.e. a two-fold increase in post-immunisation serum concentration with respect to pre-immunisation serum concentration, at 28 days after a single vaccine dose, as measured by Enzyme-Linked Immunosorbent Assay (ELISA). The percentage of subjects with a four-fold increase in post-immunisation serum concentration with respect to pre-immunisation serum concentration will be also considered
Sources of funding Bill and Melinda Gates Foundation (USA)
Trial website http://www.meningvax.org
Publications 1. 2011 results in http://www.ncbi.nlm.nih.gov/pubmed/21675889
Contact name Dr  Marie-Pierre  Preziosi
  Address Initiative for Vaccine Research
World Health Organization (WHO)
Department of Immunisation, Vaccines and Biologicals (IVB)
20 Avenue Appia
  City/town Geneva-27
  Zip/Postcode CH-1211
  Country Switzerland
  Tel +41 (0)22 791 3744
  Fax +41 (0)22 791 4860
  Email preziosim@who.int
Sponsor Serum Institute of India Limited (SIIL) (India)
  Address 212/2, Hadapsar
  City/town Pune
  Zip/Postcode 411 028
  Country India
  Sponsor website: http://www.seruminstitute.com/
Date applied 14/08/2007
Last edited 14/09/2011
Date ISRCTN assigned 14/08/2007
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.